Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 15 May 2024
Selective internal radiation therapy (SIRT) for neuroendocrine tumours metastatic to the liverStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 16 May 2024
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 24 July 2024
Fruquintinib for previously treated metastatic colorectal cancer ID6274Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 September 2024
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 September 2024
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC